What TomoWave Laboratories does

TomoWave Laboratories, Inc. is a privately held medical imaging company headquartered at 7505 Fannin Street, Suite 500, Houston, Texas. Founded in 2010 around technology invented by Dr. Alexander Oraevsky in 1993, the company develops proprietary optoacoustic (photoacoustic) tomography and laser ultrasound systems. Its core technology integrates optical excitation with ultrasonic detection to deliver high-resolution 3D volumetric imaging with both anatomical and functional/molecular information (blood content, oxygen saturation, molecular composition), without ionizing radiation or toxic contrast agents. The product portfolio includes the LOIS-3D preclinical mouse imaging system for biomedical research, the LOUISA-3D clinical breast imaging system (in development with MD Anderson Cancer Center conducting clinical trials), and additional platforms (Maestro, Symphony).

TomoWave's customers are primarily preclinical research institutions and clinical healthcare providers, with named validation partners including MD Anderson Cancer Center and Moores Cancer Center at UC San Diego. The company reports a $19M preclinical sales lead funnel and 16 validated customers in total, with technology protected across 8 international patent families. Revenue mechanics are hardware sales of specialized preclinical imaging systems sold through direct enterprise field sales on a quote basis; clinical products remain pre-commercial and are not yet FDA-cleared.

The company is currently raising a Series A convertible note to execute on its preclinical sales pipeline and advance commercial development and regulatory approvals for its clinical products, including the LOUISA-3D breast imaging system and pipeline 4D laser optoacoustic ultrasonic systems targeting diagnostics, image-guided surgery, and thermal therapy monitoring. Management is led by Dr. Alexander Oraevsky (Founder, CEO/CTO), supplemented by Angelo Ferrario (COO/CFO) and MedTech veterans from Medtronic, J&J, and Danaher. As of 2025, TomoWave was recognized by Healthcare Tech Outlook Magazine as the Top Company in Optoacoustic Imaging.

Name

TomoWave Laboratories

Legal name

TomoWave Laboratories, Inc.

Website

https://tomowave.com

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

11–50 employees

Short description

TomoWave Laboratories develops proprietary optoacoustic tomography and laser ultrasound imaging systems for preclinical research and clinical applications, primarily serving cancer research institutions and hospitals targeting cancer detection and vascular disease imaging.

Ownership category

akta.pro rank

Product category

Medical Imaging Equipment

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Mammography & Breast Imaging Systems (HLAHABAF)

akta.pro secondary industries

Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim) (HLAHABAH), Ultrasound & Echography Systems (HLAHABAD)

Keywords

• Optoacoustic imaging systems
• Photoacoustic tomography
• Preclinical imaging equipment
• Clinical breast imaging
• Laser ultrasound systems

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Preclinical Imaging Systems: Sale of LOIS-3D preclinical research imaging systems for small animal imaging with reported sales lead funnel valued at $19M
2. Clinical Imaging Systems (Pipeline): Development of clinical products including LOUISA-3D breast imaging system and 4D laser optoacoustic ultrasonic systems for diagnostics, image-guided surgery, and therapy monitoring

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

TomoWave develops and manufactures proprietary optoacoustic tomography and laser ultrasound imaging systems that combine functional/molecular and anatomical imaging. The product portfolio spans the LOIS-3D preclinical mouse imaging system, the LOUISA-3D clinical breast imaging system, and additional Maestro and Symphony imaging platforms, enabling non-invasive cancer detection and image-guided interventions without ionizing radiation.

Product overview

TomoWave Laboratories develops proprietary optoacoustic tomography and laser ultrasound imaging systems for combined functional/molecular and anatomical imaging. The product portfolio consists of pre-clinical and clinical imaging systems: LOIS-3D (pre-clinical mouse imaging for research), LOUISA-3D (clinical breast cancer imaging), Maestro and Symphony (additional imaging systems). The technology integrates optical excitation with ultrasound detection to provide high-resolution tissue images without ionizing radiation or toxic contrast agents.

Differentiator

Problem solved

Functional benefit

Brands

• LOIS-3D: Laser Optoacoustic Imaging System for pre-clinical mouse imaging
• LOUISA-3D
• Maestro
• Symphony

Products and services

• LOIS-3D Pre-Clinical Imaging System

Quantifiable outcome

• Spatial resolution of 150 microns equal in all 3 dimensions
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• MD Anderson Cancer CentercoreStrategic or Co-development PartnerKey validation partner for LOUISA-3D Clinical Breast Imaging project currently conducting clinical trials. MD Anderson is one of the world's most respected cancer research institutions, providing credibility for clinical validation.
• Moores Cancer Center at UC San DiegocoreStrategic or Co-development PartnerCancer center validating TomoWave's optoacoustic imaging technology for clinical applications.
• University of Illinois Urbana Champaign (Professor Mark Anastasio)coreStrategic or Co-development PartnerNIH-funded collaboration for LOIS-3D technology development with Professor Mark Anastasio in the Department of Biomedical Engineering.
• University of Houston (Professor Kirill Larin)minorStrategic or Co-development PartnerCollaboration with Professor Kirill Larin at the Cullen College of Engineering Department of Biomedical Engineering.
• Universidad Carlos III de Madrid (Professor Horacio Lamela Rivera)minorStrategic or Co-development PartnerInternational academic collaboration for optoacoustic imaging research.
• UTMB (Professor Massoud Motamedi)minorStrategic or Co-development PartnerCollaboration with UTMB Department of Ophthalmology and Visual Sciences Center for Biomedical Engineering.
• University of Texas Health Science Center at San Antonio (Professor Randy Glickman)minorStrategic or Co-development PartnerNanoLISA project collaboration for optoacoustic sensor development.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• iThera Medical: iThera Medical is a direct competitor in optoacoustic/photoacoustic imaging, offering preclinical MSOT in-vivo imaging systems and exploring clinical translation for oncology and inflammatory diseases. Both companies commercialize laser-based optoacoustic tomography using ultrasound detection, competing for the same research and translational imaging budgets.
• Seno Medical Instruments: Seno Medical is a direct competitor in optoacoustic breast cancer imaging, commercializing the Imagio breast imaging system that combines optoacoustic imaging with ultrasound. It targets the identical clinical workflow and dense-breast diagnostic niche as TomoWave's LOUISA-3D.

Emerging players

• Endra Life Sciences: Endra is an emerging player developing thermoacoustic imaging for fatty liver disease and preclinical imaging applications. Like TomoWave, Endra is commercializing photoacoustic-derived modalities and pursuing clinical partnerships, but with a narrower clinical focus.
• PhotoSound Technologies: PhotoSound Technologies is an emerging player providing preclinical photoacoustic imaging instruments and OEM components. It overlaps with TomoWave in optoacoustic subsystem supply and small-animal imaging but does not currently offer clinical breast systems.

Broad incumbents

• Fujifilm VisualSonics: Fujifilm VisualSonics is a broad incumbent in high-frequency preclinical ultrasound and photoacoustic imaging (Vevo systems), serving cardiovascular and cancer research. It is a comparative vendor for academic buyers choosing between traditional ultrasound and optoacoustic modalities for preclinical research.
• Hologic: Hologic is a broad incumbent in mammography and breast imaging with the dominant installed base in 3D tomosynthesis systems. Any new breast imaging entrant must compete against Hologic's sales channel, reimbursement infrastructure, and customer relationships for the same hospital radiology budgets.
• GE HealthCare: GE HealthCare is a broad incumbent across ultrasound, mammography, and molecular imaging with global distribution and clinical evidence networks. Its installed ultrasound base represents both a partnership channel and a competitive threat for optoacoustic breast imaging.
• Siemens Healthineers: Siemens Healthineers is a broad incumbent in medical imaging including ultrasound, mammography, and emerging photon-counting CT. It competes for capital imaging budgets and could acquire or build optoacoustic capability to extend its breast imaging portfolio.
• Philips Healthcare: Philips is a broad incumbent in ultrasound (including dedicated breast imaging systems) and a participant in image-guided interventions. Its enterprise sales channel is a benchmark for TomoWave's commercial ambitions in clinical imaging.
• Bruker BioSpin / Preclinical Imaging: Bruker is a broad incumbent in preclinical imaging systems including MRI and PET/CT. Academic and pharma research buyers evaluating TomoWave's LOIS-3D frequently benchmark against Bruker's installed base of small-animal imaging modalities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/tomowave-laboratories-inc.

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TomoWave Laboratories